BioTuesdays

Category - Markets

inflaRx
Markets

SVB Leerink ups InflaRx PT to $67 from $42

SVB Leerink raised its price target for InflaRx N.V. (NASDAQ:IFRX) to $67 from $42, citing a potentially larger orphan market for the company’s lead indication. The stock closed at $43.77 on April 9. “We have been...

April 10, 2019
Axsome Therapeutics
Markets

SVB Leerink starts Axsome Therapeutics at OP; PT $25

SVB Leerink initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and $25 price target. The stock closed at $14.50 on April 5. “The specialty pharma business model (using proprietary...

April 8, 2019
Arcturus Logo
Markets

HCW starts Arcturus Therapeutics at buy; PT $15

H.C. Wainwright launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $15 price target. The stock closed at $7.91 on April 4. Arcturus is focused on the development of novel messenger RNA...

April 5, 2019
Recro Pharma
Markets

Roth ups Recro Pharma PT to $10 from $7.50

Roth Capital Partners raised its price target for Recro Pharma (NASDAQ:REPH) to $10 from $7.50 but maintained a “neutral” rating, pending greater understanding of the company’s contract development and manufacturing...

April 4, 2019
iRhythm Technologies
Markets

BTIG ups iRhythm Technologies to buy; PT $80

BTIG upgraded iRhythm Technologies (NASDAQ:IRTC) to “buy” with an $80 price target, citing a drastic pullback in the stock that “opens a window of opportunity.” The stock closed at $69.34 on April 2. “For a long time...

April 3, 2019
AtriCure Logo
Markets

BTIG ups AtriCure to buy; PT $35

BTIG upgraded AtriCure (NASDAQ:ATRC) to “buy” from “neutral” with a price target of $35 based on the shares having recently slid. The stock closed at $27.37 on April 1. At a current 3.8 times enterprise value/next 12...

April 2, 2019
TG Therapeutics
Markets

Ladenburg ups TG Therapeutics PT to $39 from $27

Ladenburg Thalmann raised its price target for TG Therapeutics (NASDAQ:TGTX) to $39 from $27 after the company presented positive interim data from a Phase 2b pivotal trial in relapsed/refractory marginal zone lymphoma...

April 1, 2019
Shockwave Medical
Markets

Canaccord starts ShockWave Medical at buy; PT $39

Canaccord Genuity initiated coverage of ShockWave Medical (NASDAQ:SWAV) with a “buy” rating and $39 price target. The stock closed at $33.47 on March 29. Analyst Jason Mills writes that ShockWave’s technology –...

April 1, 2019
Proteon Therapeutics
Markets

Maxim cuts Proteon Therapeutics to hold; removes PT

Maxim Group downgraded Proteon Therapeutics (NASDAQ:PRTO) to “hold” from “buy” and withdrew its previous $5 price target after the company’s second Phase 3 study of vonapanitase failed to reach statistical significance...

March 28, 2019
Eye Point Logo
Markets

EyePoint Pharma prices $20-million stock offering

EyePoint Pharmaceuticals (NASDAQ:EYPT) priced a public offering of 10,526,500 of its common shares at a price of $1.90 each to raise about $20-million. EyePoint also granted underwriters a 30-day option to purchase up...

March 28, 2019